Alentis Therapeutics

About Alentis Therapeutics

Alentis Therapeutics is a clinical-stage biotech company focused on treating cancer and reversing fibrosis. Their mission is to advance a pipeline of anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies to unlock the therapeutic potential of Claudin-1 and bring new treatments to patients in need.

Products & Services

ADC ALE.P02:An antibody-drug conjugate targeting squamous cancers.

Lixudebart (ALE.F02):A monoclonal antibody for organ fibrosis.

Preclinical Anti-Claudin-1 Modalities:Additional ADCs and other modalities targeting Claudin-1 in development.

Specialties

Anti-Claudin-1 therapies Antibody-drug conjugates (ADCs) Monoclonal antibodies Cancer treatment Fibrosis reversal

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series D T: - FT: Series D	A: 181400000 MR: - FA: 181.4 million FAN: 181400000	D: 2024-11-12 FD: 2024-11-12	12 investors
2	RT: Series C T: - FT: Series C	A: 105000000 MR: - FA: $105 million FAN: 105000000	D: 2023-04-13 FD: 2023-04-13	6 investors

Series D Latest

2024-11-12

$181.4M

12 investors (Pro only)

Series C 2023-04-13

$105.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Jayne

Professor of Clinical Autoimmunity

J

Josep Tabernero

Head of Medical Oncology at Vall d'Hebron University Hospital, Director of the Vall d'Hebron Institute of Oncology, and Professor of Medicine at University of Vic

T

Tony Mok

Li Shu Fan Medical Foundation endowed Professor and Chairman of Department of Clinical Oncology at The Chinese University of Hong Kong

S

Steven Nathan

Medical Director and Professor

N

Nathalie Graf

Office Manager

L

Luca Santarelli

Chair

View 20 more team members with Pro

Unlock Full Team Directory

Recent News